The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. [electronic resource]
Producer: 20140218Description: 6261-72 p. digitalISSN:- 1550-6606
- Androstadienes -- pharmacology
- Antigen Presentation -- genetics
- Antigens, Neoplasm -- biosynthesis
- Cell Line, Tumor
- Epidermal Growth Factor -- pharmacology
- ErbB Receptors -- antagonists & inhibitors
- Esophageal Neoplasms -- genetics
- Extracellular Signal-Regulated MAP Kinases -- antagonists & inhibitors
- Flavonoids -- pharmacology
- Gene Expression Regulation, Neoplastic -- physiology
- Genes, MHC Class I
- HLA-A Antigens -- biosynthesis
- Humans
- Lapatinib
- MAP Kinase Signaling System -- drug effects
- Neoplasm Proteins -- antagonists & inhibitors
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- pharmacology
- Protein Processing, Post-Translational -- drug effects
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Quinazolines -- pharmacology
- RNA, Small Interfering -- pharmacology
- Receptor, ErbB-2 -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Stomach Neoplasms -- genetics
- Wortmannin
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.